



Review

Biochemical Assessment of Coenzyme Q₁₀ Deficiency

Juan Carlos Rodríguez-Aguilera ^{1,2}, Ana Belén Cortés ^{1,2}, Daniel J. M. Fernández-Ayala ^{2,3} and Plácido Navas ^{2,3,*}

¹ Laboratorio de Fisiopatología Celular y Bioenergética, 41013 Sevilla, Spain; jcrodagu@upo.es (J.C.R.-A.); abcorrod@upo.es (A.B.C.)

² Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Universidad Pablo de Olavide-CISC, 41013 Sevilla, Spain; dmorfer@upo.es

³ Centro Andaluz de Biología del Desarrollo, 41013 Sevilla, Spain

* Correspondence: pnavas@upo.es; Tel.: +34-954-349-385

Academic Editor: Iain P. Hargreaves

Received: 18 January 2017; Accepted: 28 February 2017; Published: 5 March 2017

Abstract: Coenzyme Q₁₀ (CoQ₁₀) deficiency syndrome includes clinically heterogeneous mitochondrial diseases that show a variety of severe and debilitating symptoms. A multiprotein complex encoded by nuclear genes carries out CoQ₁₀ biosynthesis. Mutations in any of these genes are responsible for the primary CoQ₁₀ deficiency, but there are also different conditions that induce secondary CoQ₁₀ deficiency including mitochondrial DNA (mtDNA) depletion and mutations in genes involved in the fatty acid β -oxidation pathway. The diagnosis of CoQ₁₀ deficiencies is determined by the decrease of its content in skeletal muscle and/or dermal skin fibroblasts. Dietary CoQ₁₀ supplementation is the only available treatment for these deficiencies that require a rapid and distinct diagnosis. Here we review methods for determining CoQ₁₀ content by HPLC separation and identification using alternative approaches including electrochemical detection and mass spectrometry. Also, we review procedures to determine the CoQ₁₀ biosynthesis rate using labeled precursors.

Keywords: coenzyme Q₁₀; CoQ₁₀ deficiency syndrome; CoQ₁₀ biosynthesis; mitochondria diseases

1. Introduction

The mitochondrial respiratory chain (MRC) generates most of the cellular ATP and is comprised of five multi-subunit enzyme complexes. Both the mitochondrial DNA (mtDNA) and the nuclear DNA (nDNA) encode for polypeptides of these complexes and also proteins involved in mitochondrial function. Besides MRC enzyme complexes, two electron carriers, coenzyme Q (CoQ) and cytochrome c, are vital for mitochondrial synthesis of ATP. Mutations in genes of either genome may cause mitochondrial diseases, which are common among inherited metabolic and neurological disorders [1].

CoQ is a lipid-soluble component of virtually all cell membranes. It is composed of a benzoquinone ring with a polyprenyl side chain, the number of isoprene units being a characteristic of given specie, e.g., 10 in humans (CoQ₁₀). CoQ₁₀ transports electrons from MRC Complexes I and II to Complex III. These electrons come from either NADH or succinate [2] although CoQ₁₀ can be alternatively reduced with electrons provided by different redox reactions in mitochondria [3]. Consequently, CoQ₁₀ is essential for ATP production inside mitochondria, although it is also an indispensable antioxidant in extramitochondrial membranes and a key factor for pyrimidine nucleotide synthesis [4].

CoQ biosynthesis depends on a pathway that involves at least 11 genes (COQ genes), showing a high degree of conservation among species, and is carried out by a putative multi-subunit enzyme complex [5]. Most of the information about the CoQ biosynthesis pathway comes from yeast, and

maintains a high homology with mammal gene components (Table 1) [6]. The CoQ₁₀ biosynthesis pathway is highly regulated by transcription factors PPAR α and NF κ B [7–9]. HuR and hnRNP C1/C2 binding proteins stabilize COQ7 mRNA as another CoQ₁₀ biosynthesis regulatory mechanism [10].

Table 1. Yeast COQ genes and their characterized human homologues.

Yeast	Human	Function
COQ1	PDSS1 */PDSS2 *	Synthesis of polyprenyl-diphosphate
COQ2	COQ2 *	<i>p</i> HB-prenyl-transferase
COQ3	COQ3 *	Methyltransferase
COQ4	COQ4 *	Organization of the multi-enzyme complex
COQ5	COQ5	Methyltransferase
COQ6	COQ6 *	Mono-oxygenase
COQ7	COQ7 *	Hydroxylase
COQ8	ADCK3 */ADCK4 *	Unorthodox kinase (regulatory)
COQ9	COQ9 *	Lipid binding protein
COQ10	COQ10A/COQ10B	CoQ chaperone
PTC7	PPTC7	Phosphatase (regulatory)

* These genes were mutated in human causing primary CoQ₁₀ deficiency.

Coq7p is post-translationally regulated in yeast that involves mitochondrial phosphatase Ptc7 [11,12]. Ptc7 human orthologue (*PPTC7*) is related to cellular bioenergetics and stress resistance [13]. Coq7p activity is a key regulator of the CoQ biosynthesis complex [6,14], which may depend on the interaction with *Coq9p* contributing to the stabilization of the biosynthesis complex [15–18]. The level of CoQ is highly regulated inside cells and tissues but its concentration is different in each tissue and organ, and depends on dietary conditions and age [19,20]. CoQ also varies greatly in human diseases such as Alzheimer's disease, cardiomyopathy, Niemann-Pick and diabetes.

2. CoQ₁₀ Deficiency Syndrome

CoQ₁₀ deficiency syndrome includes diverse inherited pathological diseases defined by the decrease of CoQ₁₀ content in muscle and/or cultured skin fibroblasts. CoQ₁₀ deficiency impairs oxidative phosphorylation and causes clinically heterogeneous mitochondrial diseases [21,22]. When the decrease in CoQ₁₀ content is due to mutations in genes encoding proteins of the CoQ biosynthesis pathway or its regulation (COQ genes), it causes primary CoQ₁₀ deficiency [23,24]. Secondary CoQ₁₀ deficiencies may be due to defects in genes unrelated to the CoQ₁₀ biosynthetic pathway. Secondary CoQ₁₀ deficiency is a common finding in oxidative phosphorylation (OXPHOS) and non-OXPHOS disorders [25]. A low mitochondrial CoQ₁₀ content is described in mtDNA depletion [26], mutations in the DNA repairing aprataxin [27], mutations of the enzyme *ETFDH* of the β -oxidation of fatty acids [28], recurrent food intolerance and allergies [29], methylmalonic aciduria [30], myalgic encephalomyelitis chronic fatigue syndrome [31], and propionic acidemia [32]. We propose that cases of secondary CoQ₁₀ deficiency associated with OXPHOS defects could be adaptive mechanisms to maintain a balanced OXPHOS which is required to keep cells alive, although the mechanisms explaining these deficiencies and the pathophysiological role in the disease are unknown.

The clinical phenotypes of primary CoQ₁₀-deficient patients are broader than initially reported in 1989 [33], including (i) a multisystem disorder with steroid-resistant nephrotic syndrome as the main clinical manifestation (*COQ1-PDSS2*) [34], (*COQ2*) [35], (*COQ6*) [36] and (*ADCK4*) [37]; (ii) a multisystem disorder without nephrotic syndrome (*COQ1-PDSS1*) [38], (*COQ9*) [39] and (*COQ7*) [40]; (iii) cerebellar ataxia (*COQ8-ADCK3*) [41–47]; and (iv) myopathy and encephalopathy (*COQ4*) [48–50].

3. Primary CoQ₁₀ Deficiency Therapy

Primary CoQ₁₀ deficiency is unique among mitochondrial diseases because an effective therapy is available for patients, which is the supplementation of CoQ₁₀. Ubiquinol, the reduced form of CoQ₁₀, was recently approved as an orphan drug for primary CoQ₁₀ deficiency [51]

While this approach is quite successful in some patients, with a clear improvement of the pathological phenotype [52], some cases do not show any clinical relief as would be expected [53], probably because they are suffering secondary CoQ₁₀ deficiency. High-dose oral CoQ₁₀ supplementation can stop the progression of the encephalopathy and allows the recovery of renal damage [52]. High-dose CoQ₁₀ supplementation was also able to prevent the onset of renal symptoms in *PDSS2*-deficient mice [54]. Furthermore, CoQ₁₀ but not other quinones can restore mitochondrial function in deficient human fibroblasts [55]. Due to the therapeutic possibility of CoQ₁₀ supplementation for these patients, a rapid and unequivocal diagnosis of the deficiency is essential.

4. CoQ₁₀ Determination in Cells and Tissues

Content of CoQ₁₀ has been determined in plasma, white blood cells, skin fibroblasts and skeletal muscle biopsies to assess a deficiency diagnosis [56–58], and recently useful determination in the urine of pediatric patients was demonstrated [59]. Although CoQ can be measured in plasma and white blood cells, you cannot use it for the diagnosis of mitochondrial diseases since CoQ content in plasma and white blood cells is often not decreased in these conditions.

CoQ₁₀ content is mainly analyzed by the injection of lipid extracts in HPLC and detected by either electrochemical and/or UV-vis detectors, or mass spectrometry. Electrochemical detection has significant advantages compared to UV-vis detection; these include higher sensitivity and also the ability to measure oxidized and reduced forms of CoQ, either separately or combined, according to differential positioning of the conditioning cell (before or after the injector valve, respectively).

CoQ₁₀ extraction from biological samples (0.5 mg protein) requires the disruption of hydrophobic elements (lipid bilayers and lipoproteins) by adding SDS (1% final concentration). Lipids are dispersed with an alcohol cocktail (2-propanol 5% in ethanol) mixed with the disrupted biological sample (ratio 1:2 *v/v*), and they undergo subsequent triplicated hexane extraction (dispersed sample:hexane ratio 3:5 *v/v*). Hexane fractions are mixed and dried under vacuum, and then reconstituted in ethanol prior to HPLC analysis. To estimate CoQ₁₀ recovery, 100 pmol CoQ₉ was included in the alcohol cocktail (2-propanol 5% in ethanol). Trace amounts of CoQ₉ may have eventually been found in human tissues (probably from dietary uptake), but this does not interfere with the significant amount of internal standard added.

For convenience in high-throughput analysis, volumes are scaled down for extraction and vortex in 1.5 mL polypropylene tubes or 2 mL cryo vials.

Separation in C18 RP-HPLC columns (5 μ m, 150 \times 4.6 mm) requires 20 mM AcNH₄ pH 4.4 in methanol (solvent A) and 20 mM AcNH₄ pH 4.4 in propanol (solvent B). A gradient method with a 85:15 solvent mixture (A:B ratio), and a flow rate of 1.2 mL/min, is regularly used as the starting conditions. The mobile phase turns to a 50:50 A:B ratio starting in minute 6 and completed in minute 8, as the flow rate decreases to 1.1 mL/min. After 20 min (run time) at 40 °C, the columns are re-equilibrated to the initial conditions for three additional minutes.

The detection of total CoQ₁₀ can be achieved either by UV-vis (set to 275 nm) or electrochemical (ECD) detectors (channel 1 set to -700 mV and channel 2 set to $+500$ mV, conditioning guard cell after injection valve). For complex samples including many peaks, the CoQ₁₀ peak is confirmed by spectral information (UV-vis) or by the redox area ratio (ECD detector, $-700/+500$ area ratio), compared to pure CoQ₁₀. Figure 1 illustrates two chromatograms that correspond to normal age-matched human dermal fibroblasts (black plot) compared to patient dermal fibroblasts with CoQ₁₀ deficiency (red plot).




Figure 1. HPLC elution profile of lipid extracts from human skeletal muscular tissue. Patient pathological profile (red plot) shows that CoQ₁₀ is clearly diminished compared to healthy control volunteers (black plot). CoQ₉ is used as internal standard for normalization.

5. Analysis of CoQ₁₀ Biosynthesis

Another important approach to assess CoQ₁₀ deficiency in cells is to determine the rate of biosynthesis by the level of incorporation of labeled CoQ₁₀ precursors such as *para*-hydroxybenzoate (*p*-HB) labeled with either ¹³C-*p*-HB or ¹⁴C-*p*-HB, which is the precursor of the benzoquinone ring, or ²H-mevalonate, which is the precursor of the isoprenyl side chain [10,60].

Polyprenyl-*p*-HB transferase activity was assayed by measuring the incorporation of ¹⁴C-*p*-HB into nonaprenyl-4-hydroxybenzoate [35]. Isolated mitochondria (0.1–1 mg protein) were mixed with assay buffer (50 mM phosphate buffer, pH 7.5, 10 mM MgCl₂, 5 mM EGTA containing 1 mM PMSF, 20 μg/mL each of the protease inhibitors chymostatin, leupeptin, antipain, and pepstatin A, 5 μM solanesyl pyrophosphate solubilized in detergent solution (1% in water), and 10⁵ DPM of ¹⁴C-*p*-HB). A sufficient volume of a 10% detergent stock solution was also added to the reaction medium to achieve a final detergent concentration of 1%. The following detergents were tested: Triton X-100, Chaps, sodium cholate, sodium deoxycholate, lysophosphatidyl choline, and octylglucoside. After incubation for 30 min at 37 °C with gentle stirring, the reaction was stopped by chilling samples to 4 °C. Prenylated ¹⁴C-*p*-HB was separated by organic extraction with hexane and then measured using a liquid scintillation counter. Specific activity was expressed as disintegrations per minute (DPM) min⁻¹·mg·protein⁻¹.

Biosynthesis of ¹⁴C-CoQ₁₀ has been quantified in any type of cell culture, such as cancer cells, human skin fibroblasts, and murine embryonic fibroblast and stem cells [10,61]. Previously, cultures were incubated with 4.5 nM ¹⁴C-*p*-HB for one to three days, depending on the cell-specific rate of growth. The ¹⁴C-*p*-HB was chemically synthesized in our laboratory from ¹⁴C-tyrosine [61]. Labeled-CoQ₁₀ content is analyzed by lipid extract injection in HPLC and detected by the radio-flow detector LB 509 with a solid cell YG 150 Al-U4D (Berthold Technologies, Bad Wildbad, Germany) in parallel with either electrochemical or UV-vis detectors. Lipid extraction is done as we described above for CoQ₁₀ determination in cells and tissues, but isocratic HPLC analysis lipid separation is performed with methanol:propanol (65:35) plus 20 mM AcNH₄ pH 4.4 at a constant flow rate of 1 mL/min (Figure 2).




Figure 2. HPLC elution profile of lipid extracts from human fibroblasts cultured with the radiolabeled precursor ^{14}C -*p*-HB. Patient pathological profile (red plot) shows that CoQ_{10} is clearly diminished compared to control cells from healthy humans (blue plot). Left Y-axis shows the radio-flow detector scale (volts). Right Y-axis shows the UV-detector scale (absorbance units) for a standard pool of CoQ_{10} and CoQ_9 (black plot). Notice that the only peak detected in this analysis corresponded with CoQ_{10} .

Alternatively, a non-radioactive protocol to analyze CoQ_{10} biosynthesis was developed using either ^2H -mevalonate or ^{13}C -phydroxybenzoate as CoQ_{10} precursors as described by Buján et al. (2014) [60]. Human fibroblasts at 60%–70% were incubated with these precursors for 24–72 h at different concentrations. After incubation, cells were trypsinized and washed twice with isotonic buffer. Pelleted cells were resuspended with 300 μL of a buffer solution containing 0.25 mmol/L sucrose, 2 mmol/L EDTA, 10 mmol/L Tris and 100 UI/mL heparin, pH 7.4, and sonicated twice for 5 s. These homogenates were used to determine CoQ_{10} biosynthesis measuring by HPLC-MS/MS, as described in Arias et al. (2012) [62]. Briefly, HPLC separation was as indicated above and extracted peaks were analyzed by MS/MS in a Micromass Quattro microTM (Waters/Micromass, Manchester, UK). The MS/MS was operated in the electrospray positive ion mode with a cone voltage (CV), and collision energy (CE) of 15 V and 20 eV, respectively. The following multiple-reaction monitoring transitions were selected: m/z 900 > 203 and 897 > 197 for ^{13}C - CoQ_{10} or ^2H - CoQ_{10} , respectively, 894 > 197 for the physiological CoQ_{10} and 826 > 197 for CoQ_9 (internal standard). The dwell time for each transition was 200 ms and the run-time was 16 min. Nitrogen (at a flow rate of 50 L/h) and argon (adjusted to obtain a vacuum of $3^\circ\text{--}10^{-3}$ bar) were used as the nebulizing and collision gas, respectively.

6. Concluding Remarks

Coenzyme Q_{10} deficiency syndrome includes a group of mitochondrial diseases showing diverse inherited pathological phenotypes. The common aspect of them is the lower content of CoQ_{10} in tissues and organs. Primary deficiency is caused by defects in proteins encoded by *COQ* genes, which are components of the biosynthesis pathway or its regulation. CoQ_{10} supplementation is the current treatment of primary CoQ_{10} deficiency, which highly improves symptoms. A rapid and distinct characterization of the deficiency is important, and it is mainly determined in skeletal muscle and/or skin dermal fibroblasts. The main approach is to analyze the total content of CoQ_{10} in lipid extracts by

HPLC and UV and/or electrochemical detection. Alternatively, the CoQ₁₀ biosynthesis rate in cultured cells can be determined by incubation with radiolabeled precursors.

Acknowledgments: This work has been funded by the Instituto de Salud Carlos III FIS PI14-01962 grant. Authors were also funded by the Junta de Andalucía BIO177 research group.

Author Contributions: J.C.R.-A., A.B.C., D.J.M.F.-A., and P.N. have contributed to writing and editing the review and figures.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Gorman, G.S.; Chinnery, P.F.; DiMauro, S.; Hirano, M.; Koga, Y.; McFarland, R.; Suomalainen, A.; Thorburn, D.R.; Zeviani, M.; Turnbull, D.M. Mitochondrial diseases, Nature reviews. *Dis. Prim.* **2016**, *2*, 16080. [[CrossRef](#)] [[PubMed](#)]
2. Lapuente-Brun, E.; Moreno-Loshuertos, R.; Acin-Perez, R.; Latorre-Pellicer, A.; Colas, C.; Balsa, E.; Perales-Clemente, E.; Quiros, P.M.; Calvo, E.; Rodriguez-Hernandez, M.A.; et al. Supercomplex assembly determines electron flux in the mitochondrial electron transport chain. *Science* **2013**, *340*, 1567–1570. [[CrossRef](#)] [[PubMed](#)]
3. Alcazar-Fabra, M.; Navas, P.; Brea-Calvo, G. Coenzyme Q biosynthesis and its role in the respiratory chain structure. *Biochim. Biophys. Acta* **2016**, *1857*, 1073–1078. [[CrossRef](#)] [[PubMed](#)]
4. Lopez-Lluch, G.; Rodriguez-Aguilera, J.C.; Santos-Ocana, C.; Navas, P. Is coenzyme Q a key factor in aging? *Mech. Ageing Dev.* **2010**, *131*, 225–235. [[CrossRef](#)] [[PubMed](#)]
5. Bentinger, M.; Tekle, M.; Dallner, G. Coenzyme Q—Biosynthesis and functions. *Biochem. Biophys. Res. Commun.* **2010**, *396*, 74–79. [[CrossRef](#)] [[PubMed](#)]
6. Gonzalez-Mariscal, I.; Garcia-Teston, E.; Padilla, S.; Martin-Montalvo, A.; Viciano, T.P.; Vazquez-Fonseca, L.; Dominguez, P.G.; Santos-Ocana, C. The regulation of coenzyme q biosynthesis in eukaryotic cells: All that yeast can tell us. *Mol. Syndromol.* **2014**, *5*, 107–118. [[CrossRef](#)] [[PubMed](#)]
7. Turunen, M.; Peters, J.M.; Gonzalez, F.J.; Schedin, S.; Dallner, G. Influence of peroxisome proliferator-activated receptor alpha on ubiquinone biosynthesis. *J. Mol. Biol.* **2000**, *297*, 607–614. [[CrossRef](#)] [[PubMed](#)]
8. Bentinger, M.; Tekle, M.; Brismar, K.; Chojnacki, T.; Swiezewska, E.; Dallner, G. Stimulation of coenzyme Q synthesis. *Biofactors* **2008**, *32*, 99–111. [[CrossRef](#)] [[PubMed](#)]
9. Brea-Calvo, G.; Siendones, E.; Sanchez-Alcazar, J.A.; de Cabo, R.; Navas, P. Cell survival from chemotherapy depends on NF-kappaB transcriptional up-regulation of coenzyme Q biosynthesis. *PLoS ONE* **2009**, *4*, e5301. [[CrossRef](#)] [[PubMed](#)]
10. Cascajo, M.V.; Abdelmohsen, K.; Noh, J.H.; Fernandez-Ayala, D.J.; Willers, I.M.; Brea, G.; Lopez-Lluch, G.; Valenzuela-Villatoro, M.; Cuezva, J.M.; Gorospe, M.; et al. RNA-binding proteins regulate cell respiration and coenzyme Q biosynthesis by post-transcriptional regulation of COQ7. *RNA Biol.* **2016**, *13*, 622–634. [[CrossRef](#)] [[PubMed](#)]
11. Martin-Montalvo, A.; Gonzalez-Mariscal, I.; Padilla, S.; Ballesteros, M.; Brautigan, D.L.; Navas, P.; Santos-Ocana, C. Respiratory-induced coenzyme Q biosynthesis is regulated by a phosphorylation cycle of Cat5p/Coq7p. *Biochem. J.* **2011**, *440*, 107–114. [[CrossRef](#)] [[PubMed](#)]
12. Martín-Montalvo, A.; González-Mariscal, I.; Pomares-Viciano, T.; Padilla-López, S.; Ballesteros, M.; Vazquez-Fonseca, L.; Gandolfo, P.; Brautigan, D.L.; Navas, P.; Santos-Ocaña, C. The phosphatase Ptc7 induces coenzyme Q biosynthesis by activating the hydroxylase Coq7 in yeast. *J. Biol. Chem.* **2013**, *288*, 28126–28137. [[CrossRef](#)] [[PubMed](#)]
13. Lanning, N.J.; Looyenga, B.D.; Kauffman, A.L.; Niemi, N.M.; Sudderth, J.; DeBerardinis, R.J.; MacKeigan, J.P. A mitochondrial RNAi screen defines cellular bioenergetic determinants and identifies an adenylate kinase as a key regulator of ATP levels. *Cell Rep.* **2014**, *7*, 907–917. [[CrossRef](#)] [[PubMed](#)]
14. Gonzalez-Mariscal, I.; Garcia-Teston, E.; Padilla, S.; Martin-Montalvo, A.; Pomares-Viciano, T.; Vazquez-Fonseca, L.; Gandolfo-Dominguez, P.; Santos-Ocana, C. Regulation of coenzyme Q biosynthesis in yeast: A new complex in the block. *IUBMB Life* **2014**, *66*, 63–70. [[CrossRef](#)] [[PubMed](#)]

15. Padilla, S.; Tran, U.C.; Jimenez-Hidalgo, M.; Lopez-Martin, J.M.; Martin-Montalvo, A.; Clarke, C.F.; Navas, P.; Santos-Ocana, C. Hydroxylation of demethoxy-Q6 constitutes a control point in yeast coenzyme Q6 biosynthesis. *Cell. Mol. Life Sci.* **2009**, *66*, 173–186. [[CrossRef](#)] [[PubMed](#)]
16. Lohman, D.C.; Forouhar, F.; Beebe, E.T.; Stefely, M.S.; Minogue, C.E.; Ulbrich, A.; Stefely, J.A.; Sukumar, S.; Luna-Sanchez, M.; Jochem, A.; et al. Mitochondrial COQ9 is a lipid-binding protein that associates with COQ7 to enable coenzyme Q biosynthesis. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, E4697–E4705. [[CrossRef](#)] [[PubMed](#)]
17. Stefely, J.A.; Licitra, F.; Laredj, L.; Reidenbach, A.G.; Kemmerer, Z.A.; Grangeray, A.; Jaeg-Ehret, T.; Minogue, C.E.; Ulbrich, A.; Hutchins, P.D.; et al. Cerebellar Ataxia and Coenzyme Q Deficiency through Loss of Unorthodox Kinase Activity. *Mol. Cell* **2016**, *63*, 608–620. [[CrossRef](#)] [[PubMed](#)]
18. Stefely, J.A.; Reidenbach, A.G.; Ulbrich, A.; Oruganty, K.; Floyd, B.J.; Jochem, A.; Saunders, J.M.; Johnson, I.E.; Minogue, C.E.; Wrobel, R.L.; et al. Mitochondrial ADCK3 Employs an Atypical Protein Kinase-like Fold to Enable Coenzyme Q Biosynthesis. *Mol. Cell* **2015**, *57*, 83–94. [[CrossRef](#)] [[PubMed](#)]
19. Parrado-Fernandez, C.; Lopez-Lluch, G.; Rodriguez-Bies, E.; Santa-Cruz, S.; Navas, P.; Ramsey, J.J.; Villalba, J.M. Calorie restriction modifies ubiquinone and COQ transcript levels in mouse tissues. *Free Radic. Biol. Med.* **2011**, *50*, 1728–1736. [[CrossRef](#)] [[PubMed](#)]
20. Lopez-Lluch, G.; Santos-Ocana, C.; Sanchez-Alcazar, J.A.; Fernandez-Ayala, D.J.; Asencio-Salcedo, C.; Rodriguez-Aguilera, J.C.; Navas, P. Mitochondrial responsibility in ageing process: Innocent, suspect or guilty. *Biogerontology* **2015**, *16*, 599–620. [[CrossRef](#)] [[PubMed](#)]
21. Schon, E.A.; DiMauro, S.; Hirano, M.; Gilkerson, R.W. Therapeutic prospects for mitochondrial disease. *Trends Mol. Med.* **2010**, *16*, 268–276. [[CrossRef](#)] [[PubMed](#)]
22. Quinzii, C.M.; Emmanuele, V.; Hirano, M. Clinical presentations of coenzyme q10 deficiency syndrome. *Mol. Syndromol.* **2014**, *5*, 141–146. [[CrossRef](#)] [[PubMed](#)]
23. Doimo, M.; Desbats, M.A.; Cerqua, C.; Cassina, M.; Trevisson, E.; Salviati, L. Genetics of coenzyme q10 deficiency. *Mol. Syndromol.* **2014**, *5*, 156–162. [[CrossRef](#)] [[PubMed](#)]
24. Desbats, M.A.; Lunardi, G.; Doimo, M.; Trevisson, E.; Salviati, L. Genetic bases and clinical manifestations of coenzyme Q10 (CoQ 10) deficiency. *J. Inherit. Metab. Dis.* **2015**, *38*, 145–156. [[CrossRef](#)] [[PubMed](#)]
25. Yubero, D.; Montero, R.; Martin, M.A.; Montoya, J.; Ribes, A.; Grazina, M.; Trevisson, E.; Rodriguez-Aguilera, J.C.; Hargreaves, I.P.; Salviati, L.; et al. Secondary coenzyme Q10 deficiencies in oxidative phosphorylation (OXPHOS) and non-OXPHOS disorders. *Mitochondrion* **2016**, *30*, 51–58. [[CrossRef](#)] [[PubMed](#)]
26. Montero, R.; Sanchez-Alcazar, J.A.; Briones, P.; Navarro-Sastre, A.; Gallardo, E.; Bornstein, B.; Herrero-Martin, D.; Rivera, H.; Martin, M.A.; Marti, R.; et al. Coenzyme Q10 deficiency associated with a mitochondrial DNA depletion syndrome: A case report. *Clin. Biochem.* **2009**, *42*, 742–745. [[CrossRef](#)] [[PubMed](#)]
27. Quinzii, C.M.; Kattah, A.G.; Naini, A.; Akman, H.O.; Mootha, V.K.; DiMauro, S.; Hirano, M. Coenzyme Q deficiency and cerebellar ataxia associated with an aprataxin mutation. *Neurology* **2005**, *64*, 539–541. [[CrossRef](#)] [[PubMed](#)]
28. Gempel, K.; Topaloglu, H.; Talim, B.; Schneiderat, P.; Schoser, B.G.; Hans, V.H.; Palmafy, B.; Kale, G.; Tokatli, A.; Quinzii, C.; et al. The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. *Brain* **2007**, *130*, 2037–2044. [[CrossRef](#)] [[PubMed](#)]
29. Miles, M.V.; Putnam, P.E.; Miles, L.; Tang, P.H.; DeGrauw, A.J.; Wong, B.L.; Horn, P.S.; Foote, H.L.; Rothenberg, M.E. Acquired coenzyme Q10 deficiency in children with recurrent food intolerance and allergies. *Mitochondrion* **2011**, *11*, 127–135. [[CrossRef](#)] [[PubMed](#)]
30. Haas, D.; Niklowitz, P.; Horster, F.; Baumgartner, E.R.; Prasad, C.; Rodenburg, R.J.; Hoffmann, G.F.; Menke, T.; Okun, J.G. Coenzyme Q(10) is decreased in fibroblasts of patients with methylmalonic aciduria but not in mevalonic aciduria. *J. Inherit. Metab. Dis.* **2009**, *32*, 570–575. [[CrossRef](#)] [[PubMed](#)]
31. Maes, M.; Mihaylova, I.; Kubera, M.; Uytterhoeven, M.; Vrydags, N.; Bosmans, E. Coenzyme Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. *Neuro Endocrinol. Lett.* **2009**, *30*, 470–476. [[PubMed](#)]

32. Fragaki, K.; Cano, A.; Benoist, J.F.; Rigal, O.; Chaussonot, A.; Rouzier, C.; Bannwarth, S.; Caruba, C.; Chabrol, B.; Paquis-Flucklinger, V. Fatal heart failure associated with CoQ10 and multiple OXPHOS deficiency in a child with propionic acidemia. *Mitochondrion* **2011**, *11*, 533–536. [[CrossRef](#)] [[PubMed](#)]
33. Ogasahara, S.; Engel, A.G.; Frens, D.; Mack, D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. *Proc. Natl. Acad. Sci. USA* **1989**, *86*, 2379–2382. [[CrossRef](#)] [[PubMed](#)]
34. Lopez, L.C.; Schuelke, M.; Quinzii, C.M.; Kanki, T.; Rodenburg, R.J.; Naini, A.; Dimauro, S.; Hirano, M. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. *Am. J. Hum. Genet.* **2006**, *79*, 1125–1129. [[CrossRef](#)] [[PubMed](#)]
35. Quinzii, C.; Naini, A.; Salviati, L.; Trevisson, E.; Navas, P.; Dimauro, S.; Hirano, M. A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. *Am. J. Hum. Genet.* **2006**, *78*, 345–349. [[CrossRef](#)] [[PubMed](#)]
36. Heeringa, S.F.; Chernin, G.; Chaki, M.; Zhou, W.; Sloan, A.J.; Ji, Z.; Xie, L.X.; Salviati, L.; Hurd, T.W.; Vega-Warner, V.; et al. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. *J. Clin. Investig.* **2011**, *121*, 2013–2024. [[CrossRef](#)] [[PubMed](#)]
37. Ashraf, S.; Gee, H.Y.; Woerner, S.; Xie, L.X.; Vega-Warner, V.; Lovric, S.; Fang, H.; Song, X.; Cattran, D.C.; Avila-Casado, C.; et al. ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. *J. Clin. Investig.* **2013**, *123*, 5179–5189. [[CrossRef](#)] [[PubMed](#)]
38. Mollet, J.; Giurgea, I.; Schlemmer, D.; Dallner, G.; Chretien, D.; Delahodde, A.; Bacq, D.; de Lonlay, P.; Munnich, A.; Rotig, A. Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders. *J. Clin. Investig.* **2007**, *117*, 765–772. [[CrossRef](#)] [[PubMed](#)]
39. Duncan, A.J.; Bitner-Glindzicz, M.; Meunier, B.; Costello, H.; Hargreaves, I.P.; Lopez, L.C.; Hirano, M.; Quinzii, C.M.; Sadowski, M.I.; Hardy, J.; et al. A nonsense mutation in COQ9 causes autosomal-recessive neonatal-onset primary coenzyme Q10 deficiency: A potentially treatable form of mitochondrial disease. *Am. J. Hum. Genet.* **2009**, *84*, 558–566. [[CrossRef](#)] [[PubMed](#)]
40. Freyer, C.; Stranneheim, H.; Naess, K.; Mourier, A.; Felser, A.; Maffezzini, C.; Lesko, N.; Bruhn, H.; Engvall, M.; Wibom, R.; et al. Rescue of primary ubiquinone deficiency due to a novel COQ7 defect using 2,4-dihydroxybenzoic acid. *J. Med. Genet.* **2015**, *52*, 779–783. [[CrossRef](#)]
41. Mollet, J.; Delahodde, A.; Serre, V.; Chretien, D.; Schlemmer, D.; Lombes, A.; Boddaert, N.; Desguerre, I.; de Lonlay, P.; de Baulny, H.O.; et al. CABPC1 gene mutations cause ubiquinone deficiency with cerebellar ataxia and seizures. *Am. J. Hum. Genet.* **2008**, *82*, 623–630. [[CrossRef](#)] [[PubMed](#)]
42. Lagier-Tourenne, C.; Tazir, M.; Lopez, L.C.; Quinzii, C.M.; Assoum, M.; Drouot, N.; Busso, C.; Makri, S.; Ali-Pacha, L.; Benhassine, T.; et al. ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency. *Am. J. Hum. Genet.* **2008**, *82*, 661–672. [[CrossRef](#)] [[PubMed](#)]
43. Horvath, R.; Czermin, B.; Gulati, S.; Demuth, S.; Houge, G.; Pyle, A.; Dineiger, C.; Blakely, E.L.; Hassani, A.; Foley, C.; et al. Adult-onset cerebellar ataxia due to mutations in CABPC1/ADCK3. *J. Neurol. Neurosurg. Psychiatry* **2012**, *83*, 174–178. [[CrossRef](#)] [[PubMed](#)]
44. Mignot, C.; Apartis, E.; Durr, A.; Lourenco, C.M.; Charles, P.; Devos, D.; Moreau, C.; de Lonlay, P.; Drouot, N.; Burglen, L.; et al. Phenotypic variability in ARCA2 and identification of a core ataxic phenotype with slow progression. *Orphanet J. Rare Dis.* **2013**, *8*, 173. [[CrossRef](#)]
45. Liu, Y.T.; Hershenson, J.; Plagnol, V.; Fawcett, K.; Duberley, K.E.; Preza, E.; Hargreaves, I.P.; Chalasani, A.; Laura, M.; Wood, N.W.; et al. Autosomal-recessive cerebellar ataxia caused by a novel ADCK3 mutation that elongates the protein: Clinical, genetic and biochemical characterisation. *J. Neurol. Neurosurg. Psychiatry* **2014**, *85*, 493–498. [[CrossRef](#)]
46. Blumkin, L.; Leshinsky-Silver, E.; Zerem, A.; Yosovich, K.; Lerman-Sagie, T.; Lev, D. Heterozygous Mutations in the ADCK3 Gene in Siblings with Cerebellar Atrophy and Extreme Phenotypic Variability. *JIMD Rep.* **2014**, *12*, 103–107. [[PubMed](#)]
47. Hikmat, O.; Tzoulis, C.; Knappskog, P.M.; Johansson, S.; Boman, H.; Sztromwasser, P.; Lien, E.; Brodtkorb, E.; Ghezzi, D.; Bindoff, L.A. ADCK3 mutations with epilepsy, stroke-like episodes and ataxia: A POLG mimic? *Eur. J. Neurol.* **2016**, *23*, 1188–1194. [[CrossRef](#)] [[PubMed](#)]
48. Salviati, L.; Trevisson, E.; Hernandez, M.A.R.; Casarin, A.; Pertegato, V.; Doimo, M.; Cassina, M.; Agosto, C.; Desbats, M.A.; Sartori, G.; et al. Haploinsufficiency of COQ4 causes coenzyme Q10 deficiency. *J. Med. Genet.* **2012**, *49*, 187–191. [[CrossRef](#)] [[PubMed](#)]

49. Brea-Calvo, G.; Haack, T.B.; Karall, D.; Ohtake, A.; Invernizzi, F.; Carrozzo, R.; Kremer, L.; Dusi, S.; Fauth, C.; Scholl-Burgi, S.; et al. COQ4 Mutations Cause a Broad Spectrum of Mitochondrial Disorders Associated with CoQ10 Deficiency. *Am. J. Hum. Genet.* **2015**, *96*, 309–317. [[CrossRef](#)] [[PubMed](#)]
50. Chung, W.K.; Martin, K.; Jalas, C.; Braddock, S.R.; Juusola, J.; Monaghan, K.G.; Warner, B.; Franks, S.; Yudkoff, M.; Lulis, L.; et al. Mutations in COQ4, an essential component of coenzyme Q biosynthesis, cause lethal neonatal mitochondrial encephalomyopathy. *J. Med. Genet.* **2015**, *52*, 627–635. [[CrossRef](#)] [[PubMed](#)]
51. Public Health. Community Register of Orphan Medicinal Products. Available online: <http://ec.europa.eu/health/documents/community-register/html/o1765.htm> (accessed on 4 March 2017).
52. Montini, G.; Malaventura, C.; Salviati, L. Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. *N. Engl. J. Med.* **2008**, *358*, 2849–2850. [[CrossRef](#)] [[PubMed](#)]
53. Pineda, M.; Montero, R.; Aracil, A.; O’Callaghan, M.M.; Mas, A.; Espinos, C.; Martinez-Rubio, D.; Palau, F.; Navas, P.; Briones, P.; et al. Coenzyme Q(10)-responsive ataxia: 2-year-treatment follow-up. *Mov. Disord.* **2010**, *25*, 1262–1268. [[CrossRef](#)] [[PubMed](#)]
54. Saiki, R.; Lunceford, A.L.; Shi, Y.; Marbois, B.; King, R.; Pachuski, J.; Kawamukai, M.; Gasser, D.L.; Clarke, C.F. Coenzyme Q10 supplementation rescues renal disease in Pdss2kd/kd mice with mutations in prenyl diphosphate synthase subunit 2, American journal of physiology. *Ren. Physiol.* **2008**, *295*, F1535–F1544. [[CrossRef](#)] [[PubMed](#)]
55. Lopez, L.C.; Quinzii, C.M.; Area, E.; Naini, A.; Rahman, S.; Schuelke, M.; Salviati, L.; Dimauro, S.; Hirano, M. Treatment of CoQ(10) deficient fibroblasts with ubiquinone, CoQ analogs, and vitamin C: Time- and compound-dependent effects. *PLoS ONE* **2010**, *5*, e11897. [[CrossRef](#)] [[PubMed](#)]
56. Yubero, D.; Montero, R.; Armstrong, J.; Espinos, C.; Palau, F.; Santos-Ocana, C.; Salviati, L.; Navas, P.; Artuch, R. Molecular diagnosis of coenzyme Q10 deficiency. *Expert Rev. Mol. Diagn.* **2015**, *15*, 1049–1059. [[CrossRef](#)] [[PubMed](#)]
57. Yubero, D.; Montero, R.; Artuch, R.; Land, J.M.; Heales, S.J.; Hargreaves, I.P. Biochemical diagnosis of coenzyme q10 deficiency. *Mol. Syndromol.* **2014**, *5*, 147–155.
58. Trevisson, E.; DiMauro, S.; Navas, P.; Salviati, L. Coenzyme Q deficiency in muscle. *Curr. Opin. Neurol.* **2011**, *24*, 449–456. [[CrossRef](#)] [[PubMed](#)]
59. Yubero, D.; Montero, R.; Ramos, M.; Neergeen, V.; Navas, P.; Artuch, R.; Hargreaves, I. Determination of urinary coenzyme Q10 by HPLC with electrochemical detection: Reference values for a paediatric population. *Biofactors* **2015**, *41*, 424–430. [[CrossRef](#)] [[PubMed](#)]
60. Bujan, N.; Arias, A.; Montero, R.; Garcia-Villoria, J.; Lissens, W.; Seneca, S.; Espinos, C.; Navas, P.; de Meirleir, L.; Artuch, R.; et al. Characterization of CoQ(1)(0) biosynthesis in fibroblasts of patients with primary and secondary CoQ(1)(0) deficiency. *J. Inherit. Metab. Dis.* **2014**, *37*, 53–62. [[CrossRef](#)] [[PubMed](#)]
61. Fernandez-Ayala, D.J.; Lopez-Lluch, G.; Garcia-Valdes, M.; Arroyo, A.; Navas, P. Specificity of coenzyme Q10 for a balanced function of respiratory chain and endogenous ubiquinone biosynthesis in human cells. *Biochim. Biophys. Acta* **2005**, *1706*, 174–183. [[CrossRef](#)] [[PubMed](#)]
62. Arias, A.; Garcia-Villoria, J.; Rojo, A.; Bujan, N.; Briones, P.; Ribes, A. Analysis of coenzyme Q(10) in lymphocytes by HPLC-MS/MS. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* **2012**, *908*, 23–26. [[CrossRef](#)] [[PubMed](#)]

